ClinicalTrials.gg
Not yet recruitingNCT07270822MASLD-DIABUpdated Apr 3, 2026

Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes

An interventional study of Collaborative care pathways group and Control group without intervention in Steatotic Liver Disease and Fibrosis of Liver, sponsored by Hospices Civils de Lyon. Not yet recruiting at 10 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,714
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 95 studies in Liver Cirrhosis with a site in France — 22 open to participants now, 25 under way, 2 of them phase 3. Liver Cirrhosis · France.

Planned enrollment
4th of 53
1,714 · median 205
Started
2026
with 4 others
No phase
29 of 95
6 open now
Primary completion
2029-03
later than 19 of 24 live
Registered
90th of 95
by date
Lead sponsor
4 of 95
Hospices Civils de Lyon

Among the 95 studies in Liver Cirrhosis with a site in France, this one is the 4th largest by planned enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2026, is one of 29 with no phase, reaches primary completion later than 19 of the 24 other live ones, and was the 90th registered.

Liver Cirrhosis

1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

22 of the 95 studies in Liver Cirrhosis with a site in France are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Liver Cirrhosis with a site in France, or all of them as a file.
02

Study summary

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global adult population, 25-30% of whom suffer from metabolic dysfunction-associated steatohepatitis (MASH), increasing the risk of progression to advanced fibrosis (AF) (fibrosis stage F3 or cirrhosis F4). Screening for AF is justified because it is associated with an increased risk of overall, hepatic, and cardiovascular mortality and therefore constitutes a public health issue.

Patients with type 2 diabetes (T2D) are identified as a priority target for screening because they are at high risk of AF related to MASLD. The recommendations of the French Association for the Study of the Liver 2020 (afef.asso.fr), the European Association for the Study of the Liver (2024), the American Association of Clinical Endocrinology (2022), and the American Association of Diabetes (2025) all recommend a two-step screening process involving the FIB-4 biological score, followed by transient elastography (TE) if the FIB-4 score is > or = 1.30. Finally, if the TE is ≥8 kPa, the patient is considered to be at intermediate/high risk of AF requiring specialized care to confirm the diagnosis and implement appropriate management, including semi-annual screening for hepatocellular carcinoma in cases of cirrhosis Despite these recommendations, their application in clinical practice remains difficult and requires multidisciplinary collaboration between diabetologists and hepatologists, and between community and hospital sectors, particularly to access TE measures.

Since 2018, the Lyon Sud diabetes department (Hospices Civils de Lyon) has implemented an in-hospital AF screening program using TE for T2D patients. However, this screening by private diabetologists has not yet been implemented, mainly due to the lack of a standardized care pathway and difficulty in accessing TE measurements.

HYPOTHESIS The implementation of systematic and standardized AF screening in private diabetes practices, in two stages and using ET in diabetes care in accordance with recommendations, would significantly increase the identification of patients with AF and thus improve their access to specialized services and appropriate care.

03

Conditions studied

  • Steatotic Liver Disease
  • Fibrosis of Liver

Keywords

  • Metabolic dysfunction-associated steatotic liver disease
  • hepatic transient elastography
  • hepatic fibrosis
  • type 2 diabetes mellitus
  • screening
  • non-invasive tests
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient, male or female
  • Type 2 diabetic patient, followed by a diabetologist in private practice participating in the study
  • Patient affiliated to a French or European healthcare insurance
  • Patient who agrees to be included in the study and who signs the form

Exclusion criteria

Exclusion Criteria:

  • Evidence of advanced fibrosis (F3 or F4 fibrosis based on the results from previous liver F3 ou F4 or evidence of cirrhosis).
  • Evidence of other causes of chronic liver disease
  • Patient who does not understand French/ is unable to give consent,
  • Patient already included in a trial who may interfere with the study
  • The subject is a pregnant or nursing female
  • Minor patient
  • Patient deprived of liberty,
  • Patient admitted to a health or social establishment for purposes other than research
  • Mentally unbalanced patients, under supervision or guardianship,
  • Patient undergoing psychiatric care
  • Patient not affiliated to a healthcare insurance plan
  • Patient already included in this screening program in the previous 12 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,714 participants (estimated)

Study arms

  • Experimental
    Collaborative care pathways group

    Collaborative development of a care pathway for the implementation of a systematic and standardized screening for hepatic AF in patients with T2D in private diabetes clinics. The care pathway will include calculation of the FIB-4 score and transient elastography measurement performed in diabetes clinics if FIB-4≥1.30, in accordance with the recommendations of the French Association for the Study of the Liver (AFEF) and the European Association for the Study of the Liver (EASL).

    Procedure: Collaborative care pathways group

  • Other
    Control group without intervention

    Current clinical routine practice with no specific intervention

    Procedure: Control group without intervention

Interventions

  • ProcedureCollaborative care pathways group

    CO-CONSTRUCTION OF THE CARE PATHWAY: Participatory approach according to scientific literature, professional practices, and experience of both healthcare providers and patients. Establishment of a working group (hospital endocrinologists, hepatologists, private practice diabetologists, representatives of patients with diabetes followed in the participating centers) to define implementation modalities, professional training, communication and information transfer between professionals, and to ensure a smooth care pathway without overloading the health system . IMPLEMENTATION: Definition of patient care pathway Training of private diabetologists to integrate FIB-4 and TE measurement into their practices Provision of the FibroScan® Monitoring of patients included in the screening program and of the number of TE measurements performed Validation of TE measurements ≥ 8 kPa in a specialized center Definition of referral procedures for patients towards the specialized center

  • ProcedureControl group without intervention

    Hepatic AF screening in patients with T2D in private diabetes clinics according to routine care

06

What researchers measure

Primary outcomes

  1. Proportion of T2D patients eligible for screening and having undergone AF screening according to the recommendations including assessment of the FIB-4 score, measurement of TE if indicated, and referral for specialized care if required

    1. Calculation of the FIB-4 score \<1.30 (automatic calculation by the medical analysis laboratory or calculated by the liberal diabetologist). 2. Calculation of the FIB-4 score ≥ 1.30 (automatic calculation by the medical analysis laboratory or calculated by the liberal diabetologist) and realization of a measurement of hepatic TE with either: * TE measurement less than 8 kPa OR * Measurement of TE greater than or equal to 8kPa and referral for specialized care to a private hepatologist, a hospital hepatology department or the Institute of Hepatology of Lyon at HCL According to the recommendations of the EASL (European Association for the Study of the Liver) and the AFEF (French Association for the Study of the Liver), screening includes both the calculation of the FIB-4 score, a transient (TE) measurement, and referral, if indicated, for specialized care. ET and FIB-4 measurements cannot be separated

    Time frame: Between 6 and 12 months following inclusion

Secondary outcomes

  1. Proportion of patients undergoing transient elastography (TE) measurement

    measurement among patients with a FIB-4 score ≥ 1.3, as documented in medical records

    Time frame: Between 6 and 12 months following inclusion

  2. Proportion of patients referred for specialized consultation for the management of MASLD

    This include referral to a private hepatologist, a hospital-based hepatology department, or the Hepatology University Hospital Institute (IHU) of Lyon at the Hospices Civils de Lyon (HCL), among those identified through screening

    Time frame: Between 6 and 12 months following inclusion

  3. Proportion of patients with TE values ≥ 8 kPa among those referred to specialized care.

    Time frame: Between 6 and 12 months following inclusion

  4. Time interval between successive steps of the screening pathway: FIB-4 assessment, TE measurement, and specialized consultation for the management of MASLD.

    Time frame: Between 6 and 12 months following inclusion

  5. Number of diabetologists not initially participating in implementing the screening pathway (FIB-4 ± TE),

    Statement of discontinuation under study.

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  6. Number of patients refusing the screening process

    Follow-up data

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  7. Number of patients eligible for the pathway.

    Number of patients included in the care pathway.

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  8. Barriers and facilitators to the implementation of the pathway at both individual and organizational levels, as reported by community-based practitioners, specialized care providers and patients.

    Interviews with patients

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  9. Patient perceptions of their participation in the implementation of the new care pathway

    Interviews with patient's perception of risk, uncertainty, anxiety induced by screening).

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  10. Fidelity of the implemented pathway to the predefined specifications, and necessary adaptations.

    % of patients with a compliant care pathway

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  11. Transferability of the intervention according to ASTAIRE criteria : characteristics of the target population

    ASTAIRE comprises 23 transferability criteria classified in four categories to analyse the comparability of settings and to facilitate transfer including : Category 1 = Typology of the included population : collection and assessment of descriptive data on the population during the initial assessment

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months.

  12. Unreliable TE measurements

    Unreliable TE measurements are defined by IQR/Median ratio ≥0,30. Results will be expressed in number of unreliable measurements

    Time frame: 2 months after inclusion (strategy implementation period)

  13. Description of the screening pathway (organization, care trajectory, professional training, patient information and education materials)

    Time frame: 10 months

  14. Proportion of screening compliance among patients with type 2 diabetes (T2D) included in the study (Follow-up period for maintaining the care pathway)

    Time frame: Between 6 and 12 months following inclusion

  15. Number of diabetologists discontinuing participation in the pathway (Follow-up period for maintaining the care pathway)

    Time frame: Between 6 and 12 months following inclusion

  16. Incremental cost-effectiveness ratio (ICER) of implementing a new screening pathway for AF on patients with type 2 diabetes followed in private diabetology practices, compared with usual care

    The outcome measure will be the rate of screenings compliant with the recommendations. The ICER will be interpreted as the additional cost generated by the new screening pathway per additional patient screened

    Time frame: Over a 12-month period

  17. Net budget impact

    Net budget impact will be assessed in euros for the Mandatory Health Insurance (MHI) at 3 years following the deployment of the new screening strategy for AF in patients with type 2 diabetes managed in private diabetology practices

    Time frame: over a 3-year horizon

  18. Transferability according to ASTAIRE criteria: nature of the intervention

    ASTAIRE comprises 23 transferability criteria classified in four categories to analyse the comparability of settings and to facilitate transfer including : Category 3 =Typology of the intervention in terms of defining objectives and planning to collect and assess descriptive elements of implementation

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months.

  19. Transferability according to ASTAIRE criteria: contextual environment

    ASTAIRE comprises 23 transferability criteria classified in four categories to analyse the comparability of settings and to facilitate transfer including : Category 2 = Typology of the environment : collection and assessment of descriptive data on the environment during the initial assessment

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months.

  20. Transferability according to ASTAIRE criteria: required implementation strategies.

    ASTAIRE comprises 23 transferability criteria classified in four categories to analyse the comparability of settings and to facilitate transfer including : Category 4 = Typology of the implementation strategies required . continuously throughout the project cycle, collect information relating to the terms and conditions of support for the transfer

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months.

  21. Inter-observer agreement between measurements performed by diabetologists and by an experienced operator in expert center

    Inter-observer agreement between measurements will explore the procedure for implementing TE in private diabetes clinics. Results will be expressed in percentage of concordant measurements

    Time frame: Throughout the implementation period up to 2 months after inclusion

  22. Single standardized description of the intervention

    The Template for Intervention Description and Replication (TIDIER reporting grid, 12 items, BMJ 2014;348:g1687) will be used. This approach ensures comprehensive and reproducible reporting of all components of the intervention.

    Time frame: Throughout the implementation period, an average of 12 months

  23. Number of diabetologists not initially participating in implementing the screening pathway (FIB-4 ± TE).

    Number of inclusions in the post-implementation phase.

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  24. Number of diabetologists not initially participating in implementing the screening pathway (FIB-4 ± TE).

    Percentage of screenings compliant with the recommendations.

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  25. Number of patients refusing the screening process

    Non-realisation of prescribed procedures.

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  26. Number of patients refusing the screening process

    Reasons

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  27. Number of patients discontinuing the screening process

    Follow-up data.

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  28. Number of patients discontinuing the screening process

    Non-realisation of prescribed procedures.

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  29. Number of patients discontinuing the screening process

    Reasons

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  30. Perceived appropriateness according to community-based and hospital-based professionals.

    Professionals' perception of the relevance and alignment of the pathway with their needs (interviews).

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  31. Barriers and facilitators to the implementation of the pathway at both individual and organizational levels, as reported by community-based practitioners, specialized care providers and patients.

    Interviews with private practitioners.

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  32. Barriers and facilitators to the implementation of the pathway at both individual and organizational levels, as reported by community-based practitioners, specialized care providers and patients.

    Focus group with specialists from the reference center (diabetologists, endocrinologists, hepatologists)

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  33. Fidelity of the implemented pathway to the predefined specifications, and necessary adaptations.

    Description of non-compliances

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  34. Fidelity of the implemented pathway to the predefined specifications, and necessary adaptations.

    Modification of the pathway

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  35. Underlying reasons for diabetologists discontinuing participation in the pathway (Follow-up period for maintaining the care pathway)

    Time frame: Between 6 and 12 months following inclusion

  36. Number of diabetologists not implementing the screening pathway (FIB-4 ± TE), and underlying reasons.

    Statement of discontinuation under study.

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  37. Number of diabetologists not implementing the screening pathway (FIB-4 ± TE), and underlying reasons.

    Number of inclusions in the post-implementation phase.

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  38. Number of diabetologists not initially participating not implementing the screening pathway (FIB-4 ± TE), and underlying reasons.

    Percentage of screenings compliant with the recommendations.

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  39. Fidelity of the implemented pathway to the predefined specifications, and necessary adaptations.

    Reasons for delays between procedures.

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  40. Fidelity of the implemented pathway to the predefined specifications, and necessary adaptations.

    Patient-professional and interprofessional relationships within the framework of the care pathway (interviews)

    Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months

  41. Reasons for diabetologists discontinuing participation in the pathway (Follow-up period for maintaining the care pathway)

    Time frame: Between 6 and 12 months following inclusion

07

Study locations

10 sites
  • Diabetology private center
    Caluire-et-Cuire, 69300, France
  • Diabetology private center
    Lyon, 69001, France
  • Diabetology private center
    Lyon, 69001, France
  • Diabetology private center
    Lyon, 69002, France
  • Diabetology private center
    Lyon, 69005, France
  • Diabetology private center
    Lyon, 69009, France
  • Diabetology private center
    Lyon, 69009, France
  • Diabetology private center
    Lyon, 69009, France
  • Diabetology private center
    Saint-Maurice-l'Exil, 38550, France
  • Diabetology private center
    Sathonay-Camp, 69580, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Mar 2029, 34 months later.

Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 34 months is close to that.

Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Dec 8, 2025
StartEst.
May 1, 2026
Primary completionEst.
Mar 1, 2029
CompletionEst.
Mar 1, 2029
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07270822
Responsible party
Sponsor
First posted
Dec 8, 2025
Start date
May 1, 2026 (estimated)
Primary completion
Mar 1, 2029 (estimated)
Completion
Mar 1, 2029 (estimated)
Last update
Apr 3, 2026

Study contacts

Cyrielle CAUSSY, MD, PhD
Contact
cyrielle.caussy@chu-lyon.fr
+33 4 78 86 44 48
Dominique DELAUNAY, PhD
Contact
+33 4 72 11 00 64

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion